Hetero Commences Generic Semaglutide Launch in International Markets

Hetero Enters Global Semaglutide Market with Multi-Year Rollout

Hetero, a Hyderabad-based drugmaker, has initiated the export of generic semaglutide to over 75 countries, accelerating competition in the global market for diabetes and obesity medicines. The move is expected to expand access to affordable GLP-1 therapies beyond developed economies, where demand is surging.

Initial Exports and Regulatory Approvals

Hetero has launched injectable semaglutide in overseas markets under the brand names Truglyx, Rolmodl, and Moto G. The initial exports are underway across parts of Africa, Asia, and the Middle East, with additional launches planned as regulatory approvals come through.

Read also: Treasury Yields Experience Largest Increase in Two Weeks Following Release of Labor Market Data

Positioning Hetero in the Market

The move positions Hetero among a growing group of manufacturers seeking to broaden access to GLP-1 drugs outside the US and Europe, where supply constraints and high prices have limited availability. Semaglutide, first developed and commercialized by Novo Nordisk, has reshaped treatment for type 2 diabetes and obesity but remains largely unaffordable in many emerging markets.

Global Supply and Distribution

Hetero is leveraging its established commercial networks across Asia, the Middle East, Africa, and Latin America to ensure consistent supply as volumes scale. The company operates in over 145 countries and has built a presence as a supplier of active pharmaceutical ingredients and finished generics to multinational drugmakers and global procurement agencies.

Read also: US-Iran Tensions Spark Uptick in Oil Prices Amid Global Market Decline

Semaglutide Portfolio

The semaglutide portfolio will be sold in multi-dose disposable pen devices designed to mirror innovator formats, and will be offered in a wide range of dose strengths, including 0.25 milligram, 0.5 milligram, 1 milligram, 2 milligrams, 1.7 milligrams, and 2.4 milligrams.

India Launch

India, one of the world's fastest-growing diabetes markets, remains a key part of Hetero's plans but will come later. The company is awaiting approval from the Central Drugs Standard Control Organisation after completing clinical trials in type 2 diabetes and obesity. A domestic launch is expected only once regulatory clearance is granted.